Adagio Medical Holdings, Inc. (ADGM) 株式分析

企業概要

Adagio Medical Holdings, Inc. is a developmental stage medical device enterprise focused on the research and development of ablation technologies designed to treat cardiac arrhythmias, specifically targeting conditions such as atrial fibrillation, atrial flutter, and ventricular arrhythmias. The company operates within the healthcare sector and the medical devices industry, a domain characterized by high regulatory barriers and a focus on innovative therapeutic solutions for cardiovascular diseases. As of the latest available data, the company holds a market capitalization of 3,132 万ドル (31.32 万ドル) while reporting no annual revenue figures and an undisclosed employee count. The market cap figure indicates that Adagio Medical is a micro-cap entity, reflecting its status as an early-stage biotechnology firm where valuation is driven primarily by the potential of its pipeline rather than current cash flows or sales volume. The absence of reported revenue and employee data further underscores the company's developmental nature, suggesting that its primary capital allocation strategy at this stage involves funding research, clinical trials, and regulatory submissions to bring its ablation technologies to commercial viability.

財務健全性

The financial statements reveal a Net Income (TTM) of -25,084,000 ドル (2508.4 万ドルの損失) and an EBITDA of -20,920,000 ドル (2092 万ドルの損失), while revenue figures are not disclosed, resulting in a 0.0% profit margin. The gap between the reported net income and EBITDA suggests significant non-operating expenses or one-time costs that impact the bottom line beyond core operations, though the lack of revenue data prevents a precise analysis of the cost of goods sold relative to sales. The company's Free Cash Flow stands at -11,178,500 ドル (1117.85 万ドルのキャッシュアウトフロー), indicating a heavy consumption of cash reserves to fund operations and development activities, which limits immediate financial flexibility but is typical for developmental stage firms. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported as 0.0%, which in the context of missing revenue data implies that the company has not yet generated commercial sales sufficient to calculate meaningful gross profitability or operational leverage. On the liability side, Adagio Medical holds Cash of 17.11M ドル (1711 万ドル) against Total Debt of 21.76M ドル (2176 万ドル), resulting in a Debt to Equity ratio of 175.44, which signifies a highly leveraged balance sheet where debt obligations substantially exceed equity capitalization. Despite the debt load, the Current Ratio is 2.44, indicating that the company possesses sufficient current assets to cover its short-term liabilities nearly two and a half times over, providing a buffer against immediate liquidity pressures. Return on Equity is reported at -155.3% and Return on Assets at -29.8%, metrics that reveal that management effectiveness is currently measured by the erosion of shareholder value and asset base due to losses rather than value creation.

バリュエーション評価

Valuation multiples for Adagio Medical are difficult to interpret using traditional metrics due to negative earnings; the P/E Ratio (TTM) is N/A, while the Forward P/E is -1.33, implying that the market prices the stock based on future expectations of profitability that have not yet materialized. The Price to Book ratio stands at 2.53, suggesting that the market values the company at 2.53 倍 times its net asset value, a premium that investors may attribute to the intangible value of its intellectual property and the potential success of its ablation technology pipeline. Alternative valuation metrics such as Price to Sales (N/A) and EV/EBITDA (-1.72) are also distorted by the company's lack of revenue and negative earnings, indicating that standard comparative valuation methods are not currently applicable. The stock price has fluctuated within a 52-Week High of 2.87 ドル and a 52-Week Low of 0.73 ドル, and without the current price explicitly provided in the facts, the relative trading position can only be described as bounded by this historical range of 2.14 ドルのスパン. The Beta is recorded at 0.04, a figure that is exceptionally low compared to the broader market, suggesting that the stock's price movements are largely decoupled from general market volatility, possibly due to its micro-cap status and low trading liquidity.

Growth & Income

Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, meaning there are no historical growth rates available to compare earnings expansion against revenue expansion, which is expected for a company in its developmental stage prior to commercial sales. Since the company does not pay dividends, the Dividend Yield is N/A and the Payout Ratio is 0.0%, indicating that the company retains all available cash flow to reinvest into its R&D efforts and operational scaling rather than distributing income to shareholders. This reinvestment strategy is typical for early-stage medical device firms, where capital is directed toward advancing clinical trials and securing regulatory approval for its ablation technologies for cardiac arrhythmias. The overall growth and income profile of Adagio Medical is currently defined by the conversion of negative earnings into future commercial potential, with no current income generation to support shareholder returns.